Agreements reached under this partnership
Business Alliances- 1
Asahi Intecc will proceed with preparations to obtain regulatory approval in Japan and, after approval is obtained, plans to begin direct sales to medical institutions in Japan through Asahi Intecc J Sales Co., Ltd., its wholly owned consolidated subsidiary.
- 2
The term of the exclusive distribution rights in Japan under this agreement is five years from the date regulatory approval is obtained. The agreement is scheduled to be renewed thereafter based on the agreement of both companies.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
This matter will have no impact on the Company Group’s consolidated results for the current fiscal year.
| Item | Details |
|---|---|
| Name of alliance partner | Nuvascular, Inc. |
| Alliance partner's business activities | Research and development, manufacture and sale of medical devices used in endovascular embolization treatment |
| Alliance partner's location | California, United States |
| Type of alliance | Business Alliances |
| Details of the alliance | Asahi Intecc will proceed with preparations to obtain regulatory approval in Japan and, after approval is obtained, plans to begin direct sales to medical institutions in Japan through Asahi Intecc J Sales Co., Ltd., its wholly owned consolidated subsidiary., The term of the exclusive distribution rights in Japan under this agreement is five years from the date regulatory approval is obtained. The agreement is scheduled to be renewed thereafter based on the agreement of both companies. |
| Contract Period | The term of the exclusive distribution rights in Japan is five years from the date regulatory approval is obtained. The agreement is scheduled to be renewed thereafter based on the agreement of both companies. |
| Date of board resolution | 14 August 2026 |
| Contract Date | 14 August 2026 |
| Impact on Business Performance | This matter will have no impact on the Company Group’s consolidated results for the current fiscal year. |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To proceed with preparations for obtaining regulatory approval and begin domestic sales after approval is obtained. Synergies are also expected with the sales network, customer base and product portfolio of its existing cerebrovascular treatment products.